Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C23H24F7N3O.CH4O3S |
Molecular Weight | 587.551 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(O)(=O)=O.C[C@@H](N(C)C(=O)N1CCNC[C@@H]1C2=C(C)C=C(F)C=C2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
InChI
InChIKey=BHECXGHXWKHZOY-DXPOFMJKSA-N
InChI=1S/C23H24F7N3O.CH4O3S/c1-13-8-18(24)4-5-19(13)20-12-31-6-7-33(20)21(34)32(3)14(2)15-9-16(22(25,26)27)11-17(10-15)23(28,29)30;1-5(2,3)4/h4-5,8-11,14,20,31H,6-7,12H2,1-3H3;1H3,(H,2,3,4)/t14-,20-;/m1./s1
Molecular Formula | CH4O3S |
Molecular Weight | 96.106 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C23H24F7N3O |
Molecular Weight | 491.445 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Vestipitant, also known as GW597599, is a neurokinin1 receptor antagonist that was being developed by GlaxoSmithKline for the treatment of postoperative nausea and vomiting. Vestipitant is one of the most potent and selective NK(1) receptor antagonists ever discovered, showing appropriate pharmacokinetic properties and in vivo activity. Its actions support the utility of NK(1) receptor blockade in the alleviation of anxiety and, possibly, depression. It was under development as a potential antiemetic and anxiolytic drug, and as a treatment for tinnitus and insomnia. Vestipitant was shown to improve sleep maintenance in patients with primary insomnia, with no associated next-day cognitive impairment. The effects on wake after sleep onset and total sleep time were maintained following repeated dosing. Vestipitant has anxiolytic properties and a good safety profile. Vestipitant was investigated for potential effect against chronic tinnitus as a stand-alone treatment and in conjunction with a selective serotonin reuptake inhibitor, paroxetine. Although well-tolerated vestipitant, alone or in combination with paroxetine, was not effective in ameliorating tinnitus in this patient group.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Discovery process and pharmacological characterization of 2-(S)-(4-fluoro-2-methylphenyl)piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]methylamide (vestipitant) as a potent, selective, and orally active NK1 receptor antagonist. | 2009 May 28 |
|
Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia. | 2013 Dec 1 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01507194
Postoperative Nausea and Vomiting: Single IV dose 6-36 mg.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18657401
Vestipitant possessed high affinity for human NK(1) receptors (pK(i), 9.4), and potently blocked Substance P-mediated phosphorylation of Extracellular-Regulated-Kinase.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:49:42 GMT 2025
by
admin
on
Mon Mar 31 18:49:42 GMT 2025
|
Record UNII |
OWR424W90Q
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C267
Created by
admin on Mon Mar 31 18:49:42 GMT 2025 , Edited by admin on Mon Mar 31 18:49:42 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
300000044504
Created by
admin on Mon Mar 31 18:49:42 GMT 2025 , Edited by admin on Mon Mar 31 18:49:42 GMT 2025
|
PRIMARY | |||
|
DBSALT002111
Created by
admin on Mon Mar 31 18:49:42 GMT 2025 , Edited by admin on Mon Mar 31 18:49:42 GMT 2025
|
PRIMARY | |||
|
CHEMBL522987
Created by
admin on Mon Mar 31 18:49:42 GMT 2025 , Edited by admin on Mon Mar 31 18:49:42 GMT 2025
|
PRIMARY | |||
|
DTXSID10187093
Created by
admin on Mon Mar 31 18:49:42 GMT 2025 , Edited by admin on Mon Mar 31 18:49:42 GMT 2025
|
PRIMARY | |||
|
24969622
Created by
admin on Mon Mar 31 18:49:42 GMT 2025 , Edited by admin on Mon Mar 31 18:49:42 GMT 2025
|
PRIMARY | |||
|
334476-64-1
Created by
admin on Mon Mar 31 18:49:42 GMT 2025 , Edited by admin on Mon Mar 31 18:49:42 GMT 2025
|
PRIMARY | |||
|
C95195
Created by
admin on Mon Mar 31 18:49:42 GMT 2025 , Edited by admin on Mon Mar 31 18:49:42 GMT 2025
|
PRIMARY | |||
|
PP-65
Created by
admin on Mon Mar 31 18:49:42 GMT 2025 , Edited by admin on Mon Mar 31 18:49:42 GMT 2025
|
PRIMARY | |||
|
OWR424W90Q
Created by
admin on Mon Mar 31 18:49:42 GMT 2025 , Edited by admin on Mon Mar 31 18:49:42 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |